List of Excipients in Branded Drug SAPROPTERIN DIHYDROCHLORIDE

Generic Drugs Containing SAPROPTERIN DIHYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	sapropterin dihydrochloride	0054-0906	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Hikma Pharmaceuticals USA Inc	sapropterin dihydrochloride	0054-0906	ASCORBIC ACID
Hikma Pharmaceuticals USA Inc	sapropterin dihydrochloride	0054-0906	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	sapropterin dihydrochloride	0054-0906	MANNITOL
Hikma Pharmaceuticals USA Inc	sapropterin dihydrochloride	0054-0906	RIBOFLAVIN

What are the Most Frequently-Used Excipients in SAPROPTERIN DIHYDROCHLORIDE?

# Of NDCs	Excipient
3	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
13	ASCORBIC ACID
1	COPOVIDONE K25-31
5	CROSPOVIDONE
13	MANNITOL

Sapropterin Dihydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Sapropterin dihydrochloride is an oral tetrahydrobiopterin therapy for phenylketonuria (PKU) and tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Its commercial opportunity is concentrated in differentiated oral formulations, pediatric adherence, palatability, dose flexibility, stability, and global access rather than in new active-ingredient patents. The principal formulation platforms are swallowable tablets and powder for oral solution. Generic competition has reduced the value of basic tablet replication, while pediatric-friendly delivery systems and specialty-market distribution remain commercially relevant.

What is sapropterin dihydrochloride used for?

Sapropterin dihydrochloride is the synthetic dihydrochloride salt of tetrahydrobiopterin, or BH4. It acts as a cofactor for phenylalanine hydroxylase and can lower blood phenylalanine concentrations in responsive patients with PKU. The U.S. label covers adults and children aged one month and older with PKU, and adults and children aged one month and older with tetrahydrobiopterin-responsive hyperphenylalaninemia caused by a deficiency of endogenous BH4 synthesis or regeneration pathways, depending on the applicable product labeling.[1]

The product is administered with a phenylalanine-restricted diet. Response is assessed through blood phenylalanine monitoring, which creates a recurring need for titration, laboratory management, caregiver education, and adherence support.

Core product characteristics

Attribute	Commercial relevance
Active ingredient	Sapropterin dihydrochloride
Pharmacologic class	Synthetic BH4 cofactor
Main indication	Phenylketonuria and selected BH4-responsive hyperphenylalaninemias
Principal dosage forms	100 mg tablets; 100 mg powder for oral solution
Primary patient population	Infants, children, adolescents and adults
Typical dosing framework	Weight-based, generally 5 to 20 mg/kg/day depending on response and labeling
Administration challenge	Large doses may require multiple tablets or reconstituted powder
Key formulation priorities	Palatability, rapid dispersibility, dosing flexibility, storage stability and excipient tolerability

What excipients are used in sapropterin products?

The originator product Kuvan uses different excipient systems for its tablet and powder presentations. U.S. labeling identifies mannitol, calcium hydrogen phosphate anhydrous, crospovidone, ascorbic acid, fumaric acid and riboflavin in the tablet formulation. The powder formulation uses mannitol, ascorbic acid, fumaric acid, sucralose and flavoring components.[1]

Kuvan tablet excipient system

Excipient	Likely formulation function
Mannitol	Diluent, mouthfeel modifier and water-soluble bulking agent
Calcium hydrogen phosphate anhydrous	Diluent and compression aid
Crospovidone	Disintegrant
Ascorbic acid	Antioxidant and pH-related stabilizing component
Fumaric acid	Acidulant and pH modifier
Riboflavin	Colorant and formulation-identification component

The tablet platform is designed for direct administration after swallowing or dispersion according to product instructions. The combination of mannitol and calcium hydrogen phosphate supports tablet mass and compression. Crospovidone helps the dosage form break apart. The acidulant and antioxidant combination may help control the chemical environment of the active ingredient.

Powder-for-solution excipient system

Excipient	Likely formulation function
Mannitol	Bulking agent and palatability aid
Ascorbic acid	Antioxidant and acidulant
Fumaric acid	pH adjustment and flavor profile
Sucralose	High-intensity sweetener
Flavoring	Taste masking and pediatric acceptability

The powder format is commercially important because it eliminates the need to swallow tablets and allows administration to younger children. It also creates a larger excipient-design window around taste, wetting, dispersion, reconstitution volume, dosing accuracy and in-use stability.

Excipients in approved generic products may differ from the originator formulation. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA pathway, but they do not generally need to copy every inactive ingredient. Differences can create opportunities for improved taste, lower excipient burden, allergen avoidance or better suitability for pediatric patients.[2]

How should manufacturers design a sapropterin excipient strategy?

A successful excipient strategy should target the product's practical limitations rather than simply reproduce the originator's ingredient list.

1. Improve pediatric palatability

Sapropterin is used extensively in children, including infants and toddlers. Taste is therefore a commercial variable that affects adherence, caregiver acceptance and persistence. The powder product already uses sucralose and flavoring, but a next-generation product could test:

• Lower-volume reconstitution.
• Improved flavor systems with reduced aftertaste.
• Multiparticulate or granule formats.
• Neutral-tasting dispersible tablets.
• Oral films or mini-tablets for age-specific dosing.
• Flavor options selected for regional preferences.

Taste masking must be balanced against pH, stability, residual moisture and compatibility with antioxidants or acidulants.

2. Reduce administration burden

Weight-based doses can require several 100 mg units each day. A product that reduces pill count or improves dose precision could compete even where generic tablets are available.

Potential platforms include:

• Higher-strength tablets, subject to dose-proportionality and bioequivalence work.
• Scored tablets or mini-tablets.
• Sachets with dose bands based on body weight.
• Dispersible tablets with rapid dissolution.
• Granules that can be mixed with a small volume of water or soft food.
• Unit-dose oral suspensions.

A higher-strength presentation could lower pill burden but would require careful control of dose flexibility, especially in infants and patients undergoing titration.

3. Control excipient exposure

PKU patients may have long treatment durations. Developers can position products around reduced exposure to selected excipients, particularly for patients who require repeated daily dosing.

Potential claims include:

• Sugar-free formulation.
• Lower sodium or mineral load.
• No artificial color.
• Reduced flavoring system.
• Allergen-controlled manufacturing.
• Lower quantity of polyols.
• Absence of lactose, gluten or gelatin where relevant to market requirements.

These claims have commercial value only if they solve a real patient or caregiver concern and remain consistent with local labeling rules.

4. Improve chemical and physical stability

Sapropterin products require control of moisture, light and chemical degradation. Ascorbic acid and fumaric acid are important formulation components, but their concentrations, particle sizes and interaction with packaging can affect stability.

Relevant development priorities include:

• Low-moisture excipient grades.
• High-barrier sachets.
• Desiccant-integrated packaging.
• Unit-dose packaging that reduces repeated opening.
• Stability after reconstitution.
• Defined hold times for prepared solutions.
• Protection from light and oxygen.
• Controlled particle size to improve dissolution and dose uniformity.

A formulation patent is more defensible when it connects a specific excipient ratio or packaging system to a measured technical effect, such as longer shelf life, reduced degradation products or improved reconstitution performance.

What formulations are commercially protected or protectable?

The active ingredient itself is mature. The stronger current opportunities are product-specific formulation, manufacturing and use claims.

Formulation patent opportunities

A developer could pursue claims covering:

• Specific acidulant-to-antioxidant ratios.
• Low-moisture powder compositions.
• Defined particle-size distributions.
• Rapidly dispersible tablets.
• Taste-masked compositions.
• High-strength tablets with demonstrated dose proportionality.
• Unit-dose sachets with improved stability.
• Reconstituted products with defined pH and stability.
• Combination products with phenylalanine-monitoring or adherence technologies.

Patent strength depends on whether the formulation produces an unexpected technical result. Broad claims covering sapropterin plus conventional excipients are vulnerable to obviousness challenges because mannitol, acids, antioxidants, sweeteners and disintegrants are familiar pharmaceutical tools.

Manufacturing and packaging claims

Manufacturing intellectual property may be more practical than composition claims. Potential claim areas include:

• Controlled-humidity blending.
• Granulation or compaction methods.
• Encapsulation of acidulants or flavor components.
• Moisture-barrier packaging.
• In-line blend uniformity controls.
• Reconstitution devices.
• Unit-dose systems that limit degradation after opening.

These claims can create barriers for competitors without requiring a novel therapeutic effect.

What is the FDA regulatory status of sapropterin products?

Kuvan received FDA approval in December 2007 for PKU.[3] FDA later approved powder for oral solution as an additional presentation. The product is regulated as a small-molecule drug, not a biologic.

Generic sapropterin products can generally enter through abbreviated new drug applications if they meet applicable requirements for pharmaceutical equivalence, bioequivalence, labeling and manufacturing quality. The powder dosage form may require more complex comparative work than a conventional immediate-release tablet because taste, reconstitution and administration conditions affect product performance.

Regulatory issues for new formulations

Product concept	Principal regulatory issue
Generic tablet	Bioequivalence, inactive-ingredient acceptability and manufacturing consistency
Powder for solution	Reconstitution, taste, dose uniformity and stability after preparation
Dispersible tablet	Dispersion time, dose recovery and administration instructions
Higher-strength tablet	Dose proportionality, safety of larger unit strength and titration flexibility
Oral film	Content uniformity, dissolution, mechanical properties and pediatric acceptability
Modified-release product	Clinical relevance of altered exposure and likely higher development burden
Combination product	Separate regulatory justification for monitoring, nutrition or adherence components

A formulation that changes absorption, food effects or dosing kinetics may require a more demanding clinical package. Commercial developers should favor improvements that preserve the established immediate-release exposure profile.

What is the Orange Book and patent status of sapropterin?

Sapropterin is a small molecule, so biosimilar approval does not apply. Generic entry is the relevant competitive pathway. Orange Book-listed patents, pediatric exclusivity, regulatory exclusivity and any litigation must be evaluated by product and jurisdiction because listings and legal status change over time.[4]

The originator's early exclusivity has expired. The commercial question is therefore not whether the active ingredient has long-term exclusivity, but whether a particular presentation has enforceable formulation, method-of-use, packaging or manufacturing protection.

Paragraph IV challenge exposure

A generic applicant may file a Paragraph IV certification against an Orange Book-listed patent if it contends that the patent is invalid, unenforceable or will not be infringed. A Paragraph IV filing can trigger litigation and, depending on the timing and applicable statutory conditions, a 30-month stay of FDA approval.[5]

For sapropterin, the greatest Paragraph IV exposure is likely to concern:

• Formulation patents.
• Pediatric dosing or responsive-patient methods of use.
• Specific dosage forms.
• Manufacturing patents.
• Crystalline or polymorphic forms, if listed and enforceable.

Because sapropterin has an established clinical and formulation history, broad secondary patents may face obviousness and written-description scrutiny. Narrow claims tied to a demonstrated stability, palatability or manufacturing benefit are more defensible.

When does sapropterin lose exclusivity?

The original active-ingredient and originator exclusivity period has already elapsed in the United States. Generic competition is therefore established or legally available, subject to product-specific approval timing and any remaining listed patent barriers.[4]

A commercial forecast should separate four dates:

1. Active-ingredient exclusivity expiration.
2. Regulatory exclusivity expiration.
3. Expiration of Orange Book-listed patents.
4. Actual first generic launch.

These dates are not interchangeable. A product may be legally approvable before a generic company launches, or an approved generic may remain commercially constrained by litigation, supply agreements, limited market size or specialty-distribution economics.

Which companies are competing in sapropterin?

The competitive field includes the originator franchise, generic pharmaceutical manufacturers and companies developing adjacent PKU therapies.

Competitive categories

Competitor category	Competitive basis
Originator sapropterin	Brand recognition, patient services, physician familiarity and specialty distribution
Generic sapropterin tablets	Lower acquisition cost and payer substitution
Generic powder products	Pediatric access and administration convenience
Pegvaliase	Alternative PKU therapy for eligible patients, generally in older populations
Medical foods and nutrition companies	Phenylalanine-restricted nutrition and adherence support
Diagnostic and monitoring companies	Blood phenylalanine testing and disease management

Pegvaliase is not a direct generic substitute for sapropterin. It is an alternative pharmacologic option with a different mechanism, administration route, patient profile and safety-management burden. Sapropterin remains differentiated by oral administration and use in BH4-responsive patients.[6]

What licensing deals affect sapropterin?

Commercial rights have historically involved originator development and regional commercialization arrangements. BioMarin developed and commercialized Kuvan, while Merck Serono participated in commercialization outside the United States under regional arrangements.[7]

For new entrants, licensing opportunities are more likely to involve:

• Regional rights for generic or branded-generic products.
• Pediatric formulation technology.
• Taste-masking systems.
• Specialty-pharmacy distribution.
• PKU diagnostic and monitoring platforms.
• Combination offerings linking drug supply with nutrition support.
• Local manufacturing for markets with procurement or access requirements.

The principal licensing asset is unlikely to be the sapropterin molecule. It is more likely to be a differentiated dosage form, a protected manufacturing process, a regulatory package or a specialty-market channel.

How strong is the patent estate for sapropterin?

The patent estate is stronger around product execution than around the molecule.

Patent area	Relative strength	Commercial assessment
Active ingredient	Low	Mature chemical entity with generic substitution
Basic immediate-release tablet	Low to moderate	Conventional excipients and manufacturing may be vulnerable
Pediatric powder	Moderate	Palatability, stability and reconstitution claims can differentiate
Taste-masked formulation	Moderate	Stronger if supported by comparative sensory and stability data
High-strength or mini-tablet platform	Moderate	Depends on dose uniformity and clinical usability
Packaging system	Moderate	Useful where linked to measured stability improvement
Method of use	Low to moderate	Patient-response and dosing claims may face prior-art challenges
Manufacturing process	Moderate	More valuable when difficult to reproduce at commercial scale
Monitoring or adherence combination	Moderate	Scope depends on whether the drug and device are integrated

A new patent program should generate comparative data early. Stability-only claims are often insufficient if the result is predictable. Data on reduced degradation, improved taste scores, lower administration error rates or superior dose recovery can improve commercial and litigation positions.

What generic launch risks exist for sapropterin?

Generic launch risk is primarily economic and operational rather than scientific.

Key risks

• Small patient population limits manufacturing scale.
• PKU treatment is chronic but specialty-distributed.
• Payers may demand substantial discounts.
• Pediatric powder development adds taste and stability complexity.
• Dose varies by body weight and response.
• Inventory must cover multiple strengths or presentations.
• Specialty pharmacies may control access.
• Physician switching may be slower for infants and complex patients.
• Medical-food products compete for the same household budget.
• Supply interruptions can damage market access in a rare disease.

A generic tablet can enter with a relatively simple value proposition: lower price. A differentiated powder or dispersible product needs evidence that caregivers value the improvement enough to overcome development and manufacturing costs.

What commercial opportunities exist in sapropterin excipients?

The highest-value opportunities are formulation-led and patient-segmented.

Opportunity 1: Pediatric powder with superior palatability

A powder product with lower reconstitution volume, improved taste and simple weight-band dosing could compete directly with generic powder products. The product should be tested across infant, child and adolescent use conditions rather than relying only on adult sensory panels.

Opportunity 2: Low-excipient burden formulation

A clean-label, sugar-free, colorant-free or allergen-controlled product could support premium positioning. The claims must be clinically and commercially meaningful, since excipient changes alone rarely justify a large price premium.

Opportunity 3: High-strength and dose-flexible tablets

A high-strength tablet could reduce pill burden in adolescents and adults. A scored or rapidly dispersible format could preserve flexibility during dose titration.

Opportunity 4: Unit-dose stability packaging

Packaging that improves shelf life, protects against humidity and simplifies travel can support both institutional procurement and direct-to-patient channels. In rare diseases, packaging convenience can influence persistence even when the active ingredient is interchangeable.

Opportunity 5: Combination adherence systems

A commercial package could combine sapropterin, dosing instructions, phenylalanine tracking, refill reminders and nutrition support. A drug-device or software component may create additional differentiation, although the regulatory pathway becomes more complex.

How does sapropterin compare with competing PKU therapies?

Factor	Sapropterin	Pegvaliase	Medical foods
Administration	Oral	Subcutaneous injection	Oral dietary products
Mechanism	BH4 cofactor and PAH responsiveness	Enzyme substitution pathway	Phenylalanine restriction
Best-established population	BH4-responsive patients, including young children	Eligible older patients with uncontrolled levels	Broad PKU population
Excipient opportunity	High in powders, dispersible tablets and pediatric formats	Lower relevance to oral excipients	High in flavor, protein source and texture
Generic risk	Direct small-molecule competition	Biologic-like specialty competition, not a traditional generic	Brand and contract-manufacturing competition
Main adherence issue	Taste, pill burden and daily administration	Injection burden and reactions	Taste, dietary fatigue and product variety

What revenue exposure does sapropterin create?

Revenue exposure depends on payer mix, generic penetration, formulation share and geographic access. The most exposed revenue is the originator tablet franchise because generic substitution is straightforward. Powder revenue may be more defensible if the manufacturer retains a meaningful pediatric adherence advantage.

A basic scenario framework is:

Scenario	Market condition	Commercial result
Generic tablet erosion	Multiple approved tablet suppliers	Rapid price and share pressure
Limited generic powder supply	Few pediatric competitors	Greater durability for powder pricing
Premium pediatric reformulation	Superior taste and dosing convenience	Potential share retention or specialty premium
Regional expansion	Improved reimbursement and local supply	Volume growth with lower unit pricing
Alternative therapy migration	Greater use of pegvaliase in older patients	Reduced adult sapropterin demand

Key Takeaways

• Sapropterin dihydrochloride is a mature small-molecule PKU therapy with established tablet and powder formulations.
• The originator's core molecule and early exclusivity no longer provide a durable commercial barrier.
• The main excipient opportunities are palatability, dispersibility, dose flexibility, stability and reduced administration burden.
• Mannitol, ascorbic acid, fumaric acid, crospovidone, calcium hydrogen phosphate, riboflavin, sucralose and flavoring are central reference excipients in the originator platforms.
• Pediatric powder is the strongest formulation-led opportunity.
• Generic tablet competition is primarily price-driven and likely to face limited patent resistance.
• Stronger secondary patents should be tied to measured technical effects, not conventional excipient combinations alone.
• Sapropterin has no biosimilar pathway because it is a small molecule.
• Licensing value is more likely to reside in formulation technology, specialty distribution or patient-support systems than in the active ingredient.
• Commercial forecasts should model generic launch timing, powder substitution, payer discounts, patient switching and regional distribution separately.

FAQs

Can sapropterin powder be reformulated without sucralose?

Yes. A developer can use another sweetener or taste-masking system if the product meets stability, safety, bioequivalence and labeling requirements. The replacement must not compromise dose uniformity or administration instructions.

Is a liquid sapropterin formulation commercially attractive?

It can be attractive for infants and patients unable to swallow tablets, but liquid formulations create higher stability, preservative, microbial-control, packaging and in-use-life requirements. A dry powder or dispersible tablet may offer a lower-risk route.

Can excipient changes support a new sapropterin patent?

Yes, but the strongest applications should claim a defined composition or process linked to unexpected results, such as improved chemical stability, superior taste, lower degradation or better dose recovery.

Are sapropterin tablets interchangeable with sapropterin powder?

They are not automatically interchangeable from a practical-use perspective. The dosage form, reconstitution method, administration volume, excipients and labeling instructions differ. Regulatory substitution depends on the specific approved product and applicable pharmacy rules.

Does sapropterin require cold-chain distribution?

Commercial handling requirements depend on the approved product label and packaging system. A formulation with enhanced humidity and temperature stability could reduce distribution costs, but the claim would require supporting stability data under relevant conditions.

References

1. U.S. Food and Drug Administration. (2023). Kuvan (sapropterin dihydrochloride) tablets and powder for oral solution: Prescribing information. BioMarin Pharmaceutical Inc.

2. U.S. Food and Drug Administration. (2014). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2007). FDA approves Kuvan for phenylketonuria. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2018). Palynziq (pegvaliase-pqpz) prescribing information. U.S. Department of Health and Human Services.

7. BioMarin Pharmaceutical Inc. (2008). Annual report on Form 10-K. U.S. Securities and Exchange Commission.